Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19688 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Christian Fynbo Christiansen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Blood Platelets, Purpura, Thrombocytopenic, Idiopathic, Recombinant Fusion Proteins, Thrombopoietin. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen.
Abstract (Originalsprache)
Patient characteristics and platelet responses at romiplostim initiation according to the duration of immune thrombocytopenia (ITP) are poorly understood. Amongst romiplostim‐exposed adults with ITP lasting ≥6 months during 2009–2018 in Denmark, Sweden, and Norway, we examined characteristics at romiplostim initiation, romiplostim dosage, and durable platelet response (≥75% of measurements ≥50 × 10 9 /L at 14–24 weeks) for subcohorts with newly diagnosed (duration 12 months) ITP initiating romiplostim. The 285 romiplostim initiators comprised 81 (28%) with newly diagnosed, 47 (16%) with persistent, and 157 (55%) with chronic ITP. More patients with newly diagnosed ITP than longer ITP duration, had low comorbidity levels, two or more prior ITP therapies, and previous bleeding requiring hospitalisation. The median romiplostim doses were similar across subcohorts. During treatment, median platelet counts were similar across subcohorts (75–76 × 10 9 /L), and the durable platelet response was 64.6%, 52.9%, and 52.7% for newly diagnosed, persistent, and chronic ITP, respectively. After treatment cessation, the median platelet count was 138 × 10 9 /L, 68 × 10 9 /L, and 71 × 10 9 /L, respectively. In conclusion, newly diagnosed patients, compared with romiplostim initiators with longer disease duration, had more severe ITP, higher frequency of durable platelet response, and higher median platelet count after cessation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
- Department of Medicine, Østfold Hospital Trust, Grålum, Norway.
- Department of Hematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Clinical Epidemiology Division and Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
- Center for Observational Research, Amgen, Uxbridge, UK.
- Center for Observational Research, Amgen, Thousand Oaks, California, USA.
ORCID-Profile: Christian Fynbo Christiansen, Waleed Ghanima
Förderung
- Amgen
Zitieren
APA
Christiansen, C. F., Risbo, N., Ghanima, W., Linder, M., Bahmanyar, S., Seesaghur, A., Clouser, M., Nørgaard, M., & Sørensen, H. T. (2024). Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway. British Journal of Haematology. https://doi.org/10.1111/bjh.19688
Vancouver
Christiansen CF, Risbo N, Ghanima W, Linder M, Bahmanyar S, Seesaghur A, et al. Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway. British Journal of Haematology. 2024. doi:10.1111/bjh.19688
BibTeX
@article{Christiansen2024,
author = {Christiansen, Christian Fynbo and Risbo, Nickolaj and Ghanima, Waleed and Linder, Marie and Bahmanyar, Shahram and Seesaghur, Anouchka and Clouser, Mary and Nørgaard, Mette and Sørensen, Henrik Toft},
title = {Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19688}
}
EUVIMED